Roche to acquire Memory Pharmaceuticals



New research in an animal model suggests that a diet high in inorganic phosphates, which are found in a variety of processed foods including meats, cheeses, beverages, and bakery products, might speed growth of lung cancer tumors and may even contribute to the development of those tumors in individuals predisposed to the disease. The study

Full Post: Diet high in inorganic phosphates increases risk of lung cancer

Roche and Memory Pharmaceuticals has announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million.

Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer’s disease and schizophrenia. Memory Pharmaceuticals’ nicotinic alpha-7 agonist drug candidates in these disease areas are already in partnered programmes with Roche: R3487/MEM 3454 is in phase II clinical trials for Alzheimer’s disease and schizophrenia; R4996/MEM 63908 is in phase I for Alzheimer’s disease.

“Acquiring Memory Pharmaceuticals will enable Roche to secure the future development of its promising nicotinic alpha-7 agonists,” said William Burns, CEO Division Roche Pharmaceuticals. “The innovative work carried out by the scientists at Memory Pharmaceuticals will be fully integrated into Roche’s R&D portfolio with the aim of providing new hope for patients and caregivers affected by devastating diseases such as Alzheimer’s.”

Jonathan Fleming, Chairman of the Board of Directors of Memory Pharmaceuticals said: “Since founding Memory Pharmaceuticals in 1998, we have focused on developing medicines that could make a real difference to the lives of CNS patients. I am proud of the progress our dedicated team has made and I am confident that Roche’s capabilities and experience in the CNS field will enable our research to realise its full potential.”

http://www.memorypharma.com/

Link




Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and

Full Post: Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists



Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12×135K format for analysis of DNA copy number variation. NimbleGen CGH 12×135K arrays allow simultaneous analysis of 12 independent sample pairs on a single microarray slide, each with 135,000 empirically tested long oligonucleotide probes. This new array format will enable rapid and

Full Post: Roche NimbleGen launches microarrays for analysis of DNA copy number variation



Roche announced today that its innovative dual-target HIV-1 test has received CE Mark certification, allowing it to be sold for clinical use in the European Union. The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome. This approach provides reliable test

Full Post: Roche’s new dual-target HIV-1 test approved in Europe



Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda’s resubmission of the iloperidone New Drug Application (NDA). Vanda’s resubmission was a Complete Response to the not approvable action letter that the company received on July

Full Post: FDA accepts Vanda Pharmaceuticals Iloperidone resubmission



In one of the first instances of targeted drug design in psychiatric treatment, University of Pittsburgh researchers have found an experimental agent that shows promise in addressing working memory impairments that occur in schizophrenia. The study breaks new ground in the strategy used to develop new pharmacological treatments for schizophrenia, explained David Lewis, M.D., UPMC

Full Post: Breakthrough in strategy used to develop new pharmacological treatments for schizophrenia